WAYNE, Pa.--(BUSINESS WIRE)--Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/dusa) is investigating potential claims against the board of directors of DUSA Pharmaceuticals Inc. (“DUSA” or the “Company”) (NASDAQ: DUSA) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Sun Pharmaceutical Industries Limited in an all-cash deal valued at approximately $230 million.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of DUSA. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at firstname.lastname@example.org or visit: www.rmclasslaw.com/cases/dusa
Under the terms of the proposed transaction, DUSA’s stockholders will receive $8 in cash for each share of DUSA common stock they own.
If you own shares of DUSA and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/dusa. You may also email Mr. Maniskas at email@example.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.